Targets › CA12
1 program from 1 company in 20 trials: 8 Phase 1, 6 Phase 2, 5 Phase 4, 1 Phase 3; Neurology, Cardiovascular, Metabolic and endocrine; next expected readout Dec 2026.
Reversible hydration of carbon dioxide. (UniProt, O43570)
Open in Phaseline: the race on CA12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shionogi | Acetazolamide Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor | CA1, CA2, CA12, CA4 | Phase 2 | Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain … | Dec 2026 |
Sleep Apnea (3) Obstructive Sleep Apnea (3) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1) Sleep Disordered Breathing (1) Acute Heart Failure (1) Type 1 Diabetes (1) Acute Decompensated Heart Failure (1) Central Sleep Apnea Comorbid With Opioid Use (1) Malignant Glioma of Brain (1) Tumor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.